Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII

BACKGROUND AND OBJECTIVE: Emicizumab is a monoclonal antibody that bridges activated coagulation factor IX and factor X to restore effective hemostasis in persons with hemophilia A. It is indicated for routine prophylaxis of bleeding episodes in persons with hemophilia A. The aim of the present stud...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Pharmacokinet
Huvudupphovsmän: Jonsson, Fredrik, Schmitt, Christophe, Petry, Claire, Mercier, Francois, Frey, Nicolas, Retout, Sylvie
Materialtyp: Artigo
Språk:Inglês
Publicerad: Springer International Publishing 2021
Ämnen:
Original Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC8249270/
https://ncbi.nlm.nih.gov/pubmed/33709296
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-021-01006-0
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk